Department of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Department of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
Oral Oncol. 2019 Jan;88:39-48. doi: 10.1016/j.oraloncology.2018.11.021. Epub 2018 Nov 20.
Delays in the initiation of postoperative radiation have been associated with worse outcomes; however, the effect of the overall treatment package time (interval from surgery through the completion of radiation) remains undefined. The purpose of this study was to determine the impact of package time on survival and to evaluate this effect among different subgroups of head and neck cancer patients.
In this observational cohort study, the National Cancer Database was used to identify 35,167 patients with resected nonmetastatic head and neck cancer who underwent adjuvant radiation from 2004 to 2014. Kaplan-Meier survival estimates and multivariate Cox regression analyses were performed to determine the effect of treatment package time on overall survival.
Median package time was 96 days (interquartile range, 85-112 days). After adjusting for covariates, package times of 11 weeks or less were associated with improved survival (adjusted hazard ratio (aHR), 0.90; 95% confidence interval, 0.83-0.97) compared to an interval of 12-13 weeks, whereas package times of more than 14 weeks were associated with worse survival (aHR, 1.14, 1.14, and 1.22 for 14-15, 15-17, and >17 weeks, respectively). A significant interaction was identified between package time and disease site, nodal status, and stage. Specifically, patients with oropharyngeal tumors, advanced stage (III or IV) disease, or nodal involvement experienced more pronounced increases in mortality risk with delays in treatment time.
Treatment package time independently impacts survival. This effect may be strongest for patients with oropharyngeal tumors or advanced stage disease.
术后放疗开始时间的延迟与预后较差有关;然而,整体治疗方案时间(从手术到放疗完成的时间间隔)的影响仍未确定。本研究旨在确定方案时间对生存的影响,并评估其在头颈部癌症患者不同亚组中的作用。
在这项观察性队列研究中,国家癌症数据库被用于确定 35167 名 2004 年至 2014 年间接受辅助放疗的局部切除非转移性头颈部癌症患者。采用 Kaplan-Meier 生存估计和多变量 Cox 回归分析来确定治疗方案时间对总生存的影响。
中位方案时间为 96 天(四分位间距,85-112 天)。在校正了协变量后,与 11 周或更短的治疗间隔相比,11 周或更短的治疗间隔与生存改善相关(调整后的危险比(aHR),0.90;95%置信区间,0.83-0.97),而 14 周或更长的治疗间隔与生存恶化相关(aHR 分别为 1.14、1.14 和 1.22,用于 14-15、15-17 和 >17 周)。方案时间与疾病部位、淋巴结状态和分期之间存在显著的交互作用。具体来说,患有口咽肿瘤、晚期(III 或 IV 期)疾病或淋巴结受累的患者,随着治疗时间的延迟,其死亡风险增加更为显著。
治疗方案时间独立影响生存。对于患有口咽肿瘤或晚期疾病的患者,这种影响可能最强。